Related Experiment Video
Updated: Jul 18, 2026

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
Overexpression of alpha-synuclein following methamphetamine: is it good or bad?
Giuseppe Mauceli1, Carla I Busceti, Antonio Pellegrini
1Department of Human Morphology and Applied Biology, University of Pisa, Via Roma, 55, I-56126 Pisa, Italy. f.fornai@med.unipi.it
Abstract:
alpha-Synuclein is a presynaptic protein involved in various degenerative disorders now defined as synucleinopathies. These include neurological diseases that share a few pathological features consisting of aggregates of both normal and altered alpha-synuclein within specific neuronal populations and/or glial cells. The prototype of synucleinopathies is represented by Parkinson's disease (PD) in which alpha-synuclein is identified as a constant component of neuronal pale eosinophilic inclusions: "the Lewy Bodies." In the present article, we discuss the potential significance of amphetamine-induced overexpression of alpha-synuclein in light of clinical findings showing neurodegeneration following overexpression of alpha-synuclein and recent experimental studies that measured increased expression of alpha-synuclein following amphetamine derivatives.
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Parkinson Disease ll: Pathophysiology
Drugs Affecting Neurotransmitter Release or Uptake

